JAK
Janus kinase
JAK アイソフォーム特異的製品
All Product Categories
-
JAK Inhibitors
(531)
View all products
-
JAK Agonists
(2)
View all products
-
JAK Antagonists
(4)
View all products
-
JAK Activators
(23)
View all products
-
JAK Modulators
(7)
View all products
-
JAK Inducer
(1)
View all products
-
JAK Degraders
(12)
View all products
-
JAK Control
(1)
View all products
-
JAK Substrate
(1)
View all products
-
JAK Ligands
(5)
View all products
-
Janus Kinase 1 (JAK1) Proteins
(4)
View all products
-
JAK 関連製品 (617)
関連製品 (617)
-
組換えタンパク質 (4)
-
抗体 (7)
-
JAK Isoform Comparison
-
Ruxolitinib
0 Images別名: INCB18424 -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Tofacitinib
0 Images別名: Tasocitinib; CP-690550Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Upadacitinib
0 Images別名: ABT-494Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Baricitinib
0 Images別名: LY3009104; INCB028050 -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Deucravacitinib
0 Images別名: BMS-986165Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
PROTAC SKP2 Degrader-1
0 ImagesPROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a Kd value of 6.28 μM. PROTAC SKP2 Degrader-1 induces targeted degradation of SKP2 via the ubiquitin-proteasome system. PROTAC SKP2 Degrader-1 stabilizes the expression of SOCS1 and regulates the expression of immunoproteasomes through the JAK/STAT pathway, thereby inhibiting tumor cell proliferation. PROTAC SKP2 Degrader-1 is applicable for cancer-related research. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
RAI-20
0 Images別名: H018RAI-20 (H018) is an orally active JAK1/JAK2 dual inhibitor (IC50=15.1 and 22.7 nM). RAI-20 exhibits excellent pharmacokinetic properties, including plasma stability, systemic exposure, and a long half-life. In a collagen-induced arthritis rat model, RAI-20 shows significant anti-inflammatory and anti-arthritic activities, effectively reducing paw swelling volume and arthritis index. RAI-20 can be used for research on the pathogenesis of rheumatoid arthritis. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
YYSW001
0 Images製品番号: HY-182359CAS 番号: 2763672-36-0YYSW001 is a selective and orally acrive JAK1 inhibitor with an IC50 of 6 nM and a Kd of 32.32 μM. YYSW001 blocks JAK1-dependent phosphorylation of STAT6, as well as IL-6-induced phosphorylation of STAT3. YYSW001 suppresses pro-inflammatory cytokine levels, reduces paw swelling, lowers clinical arthritis scores, alleviates joint damage and decreases bone loss. YYSW001 is applicable for the research of rheumatoid arthritis. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Fedratinib
0 Images別名: TG-101348; SAR 302503Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
- AG490 (AG490)
-
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
- Ruxolitinib phosphate
-
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Pentagalloylglucose
(Pentagalloylglucose)
0 Images別名: Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucosePentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Tofacitinib citrate
(Tofacitinib (citrate))
0 Images別名: トファシチニブクエン酸塩; Tasocitinib (citrate); CP-690550 (citrate)Tofacitinib citrate is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Ritlecitinib
(Ritlecitinib)
0 Images別名: リトレシチニブ; PF-06651600Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE). -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
- Pacritinib
-
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
- WP1066 (WP1066)
-
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
- Momelotinib
-
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
- Butyzamide
-
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Gamma-glutamylcysteine
(Gamma-glutamylcysteine)
0 ImagesGamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
-
Icaritin
(Icaritin)
0 Images別名: Anhydroicaritin; イカリチンIcaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC50 of 8 µM) and primary CML cells (IC50 of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis[3. -
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityお問い合わせ
August 31
-
Please select quantity
August 31
お問い合わせ
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.